Sichenzia Ross Ference Carmel LLP represents INmune Bio Inc. in $13.0 Million Registered Direct Offering

Press Release – New York, NY – September 17, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented INmune Bio (Nasdaq: INMB), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, in the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to an aggregate of 2,341,260 shares of common stock at a combined purchase price per share and accompanying warrant of $5.50 for the institutional investors, and $6.50 per share and accompanying warrant for the Insiders, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $13.0 million before deducting placement agent fees and other estimated offering expenses

A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.

The SRFC team was led by partners Marc Ross,  Thomas Rose, and David Manno, and associate Jesse Blue.